Pharmaceutical companies are pouring billions of dollars into artificial intelligence (AI), hoping to revolutionize drug development. Much of this investment is focused on improving early-stage discovery — where AI excels at generating and optimizing new molecules. However, industry observers note that this phase represents the least costly part of the drug development pipeline, while the most significant failures still occur later, during the critical transition from preclinical studies to clinical trials. New NAM technologies can help closing this critical gap.

Dr. Arne-Christian Faisst, Founder & CEO of abc biopply ag, and Dr. Yuki Yamamoto, Co-founder & CEO of HiLung Inc., will share insights into the latest advancements in Micro-Physiological Systems (MPS) and organoid research on the 26th November 2025 from 09:00-10:00 CET

Over the past two years, our CEO Arne-Christian Faisst from anfass Life Technologies has been able to accompany the start-up Bonebridge on its way to the market as one of the experts from the Swiss Entrepreneurs Fundation as part of the UpScaler program.

It is our pleasure to introduce Naime Demiri, the newest addition to our team at anfass Life Technologies. Ms. Demiri will be in charge of the financial accounting for the entire group.

We are delighted to announce that our portfolio company, 4D Lifetec, was a standout participant at the SACHS ASSOCIATES 5th Annual European HealthTech CEO Forum for Partnering and Investment held on February 27, 2024. 4D Lifetec’s CEO, Dr. Giancarlo Rizzoli, represented the company as a distinguished panelist on the captivating topic, "New Frontiers in Personalized Medicine with AI Powered Diagnostics."

Experience the future of cancer diagnostics through anfass Life Technologies AG, where 4D Lifetec, a prominent portfolio company, is leading the charge. In a recent in the local newspaper Solothurner Zeitung, Dr. Giancarlo Rizzoli, CEO of 4D Lifetec, sheds light on the groundbreaking strides made by the company.

It is with great pleasure that we announce that our portfolio company, 4D Lifetec AG, has achieved a groundbreaking success. In close partnership with Xlife Sciences AG, 4D Lifetec not only receives a valuable financial investment of CHF 23.3 million, but also advanced AI technology. This innovation will pave the way for revolutionary early cancer detection and expansion of presence in the US. Read more about this milestone in the latest Genomweb post.

This year's European HealthTech CEO Forum (EHTF) on 28. February 2023 was a great success. Dr. Arne-Christian Faisst participated as a panelist in the exciting discussion about future personalized patient care in the "Revolutionizing Patient Care: Personalized Medicines & Diagnostics Panel".

We are pleased to announce that our CEO and owner, Dr. Arne-C. Faisst, will be one of the panelists of the "Revolutionizing Patient Care: Personalized Medicines & Diagnostics Panel" at the upcoming 4th annual European HealthTech CEO Forum (EHTF) on February 28, 2023 in Zurich.

We are pleased to welcome Liv Enya Torresan as a new member to our anfass Life Technologies team. Ms. Torresan will take the responsibility for all digital marketing activities for our group.

Halder has acquired a majority stake in the family-run CPM Group. In doing so, the company is taking over a high-performance management team that has already been working together successfully in its composition for years. anfass Life Technologies has already been working with the Frankfurt-based financial investor Halder on various projects since 2020 and has provided a member of the CPM Group's advisory board since September 2022.

Swiss family office anfass Life Technologies and the German investment firm Picus Capital will be cooperating in financing early-stage startups in the future. Both companies take a long-term approach to their investments and are strengthening their activities in Switzerland and Germany through the collaboration.

anfass Life Technologies has assisted 4D Lifetec AG, one of our Medtech/Diagnostics portfolio companies, in placing and successfully closing a CHF 1.9 million Series B financing for the market launch of its liquid biopsy assay 4D Lifetest™ Lung Dx for the early detection of lung cancer in Europe. We congratulate and wish the company ongoing success.

Since 2017 this abc biopply is a part of anfass Life Technologies biotech portfolio. The company now has reported last year’s revenues up more than twice in its strategic core business.

Since 2019, anfass Life Technologies has been supporting suvema AG in supplementing its organic growth strategy with strategic external components. The now successfully completed acquisition of newemag AG creates the new market leader for technology partnerships in the field of customized CNC-controlled machine tools in the Swiss market.

anfass Life Technologies AG, known for its activity as an incubator of innovative ideas and projects, supports with the project Aaregondel an innovative mobility concept for regional public transportation in Solothurn.

We congratulate Borer Chemie AG on the successful organization of this year's Industry Day of the INVESO with around 80 guests from politics and business in Solothurn.

As a logical next step in the company's development, BKW Building Solutions AG has taken over the entire share capital of the company and is now the full owner of alphaTrust.ch ag.

The two life science companies have entered into a collaboration for the co-development of highly effective antibodies without animal testing. For this purpose, Quadira Biosciences AG has been founded as a joint venture.

We are very proud that one of our Swiss portfolio companies is developing so promisingly and is now by signing a collaboration agreement with an U.S.-listed company already being internationally acknowledged.

Our most recent investment is in a new company that provides solutions for accurate and rapid pathogen detection for industrial applications.

Congratulations to this further, very important milestone.

Our employee Jacqueline Felber has successfully finished her CAS degree in Digital Marketing and Transformation.

Since 2014, anfass Life Technologies AG has been supporting a Swiss start-up that aims to establish itself in the early detection of cancer.

Since 2014 anfass Life Technologies AG acts as lead investor for abc biopply ag and is providing management and marketing support. Together with the launch of the company’s new technology platform 3D CoSeedis™ our anfass LT marketing has now launched abc biopply`s new exciting web presence.

Our participaton at the Future Health Conference in Basel has been very valuable to us.

Thank you to our guests for the great evening and admiration for the artist Renu G.

We are pleased to introduce you our new team member.

We honour our Senior Client Partner Giancarlo Rizzoli.

anfass Life Technologies AG looks back on a successful year 2016.

For a Swiss start-up, anfass Life Technologies had to be able to organize a scientific event. For that we summoned internationally renowned researchers to Solothurn.

For the first time in Switzerland, people will be able to admire photos from the photo collection "Fascination Water - the sculptural and graphical art of water" by Steffen Faisst.

On the 29th April 2016, anfass Life Technologies AG threw an Open Office Day to celebrate the purchase of new premises at a new location with friends, partners and neighbours.